Verrica Pharmaceuticals INC

Verrica Pharmaceuticals Inc. held its 2026 Annual Meeting of Stockholders, approving an equity incentive plan and ratifying auditor selection.

Verrica Pharmaceuticals announced first quarter 2026 financial results, highlighting record demand for YCANTH and progress in its clinical development programs.

Verrica Pharmaceuticals announced the appointment of Charles Frantzreb to its Board of Directors and approved significant equity compensation for its CEO and Interim CFO.

Verrica Pharmaceuticals announced a $50 million private placement to retire debt and extend its cash runway into mid-2027, alongside board changes.

Verrica Pharmaceuticals reported a significant increase in third-quarter 2025 revenue, driven by YCANTH sales and milestone payments, alongside positive regulatory feedback for its pipeline assets.

Verrica Pharmaceuticals Inc. announced a return to profitability in Q2 2025, driven by strong YCANTH sales growth and a significant milestone payment, while also regaining Nasdaq compliance.

Verrica Pharmaceuticals Inc. reported significantly increased revenue and a substantial reduction in net loss for the nine months ended September 30, 2025, driven by YCANTH sales and collaboration milestones, despite ongoing liquidity concerns.

Verrica Pharmaceuticals reports Q2 2025 results with increased collaboration revenue but acknowledges substantial doubt about its ability to continue as a going concern.

Verrica Pharmaceuticals reports Q1 2025 results, highlighting revenue growth but also raising concerns about its ability to continue as a going concern due to liquidity challenges and debt obligations.

Verrica Pharmaceuticals' Q3 2024 results reveal a net loss and concerns about its ability to continue as a going concern, despite ongoing commercialization efforts.

Verrica Pharmaceuticals reported its Q2 2024 financial results, highlighting increased revenue but also significant operating losses and concerns about its ability to continue as a going concern.

Verrica Pharmaceuticals reported a net loss of $20.3 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.

Verrica Pharmaceuticals announces its FY2024 results, highlighting YCANTH sales growth while acknowledging substantial doubt about its ability to continue as a going concern.

Verrica Pharmaceuticals' 2023 annual report details the commercial launch of YCANTH for molluscum contagiosum, ongoing clinical trials, and financial results including a net loss of $67 million.

Lawrence Eichenfield, a Director at Verrica Pharmaceuticals Inc., acquired stock options for 16,000 shares of common stock.

Verrica Pharmaceuticals Inc. director Diem Nguyen acquired 16,000 stock options with an exercise price of $6.04, vesting over 12 months starting July 5, 2026.

Verrica Pharmaceuticals Inc. director Mark A. Prygocki Sr. acquired 16,000 stock options with an exercise price of $6.04.

Gavin Corcoran, a Director at Verrica Pharmaceuticals Inc., acquired stock options for 16,000 shares.

Verrica Pharmaceuticals' Interim CFO, John J. Kirby, acquired 10,000 shares of common stock through a fully vested restricted stock unit award.

Verrica Pharmaceuticals' Chief Medical Officer, Noah L. Rosenberg, acquired 2,357 shares of common stock and 589 Series C warrants.

Verrica Pharmaceuticals Inc. has issued its 2026 proxy statement detailing director elections, executive compensation, and a proposed amendment to its 2018 Equity Incentive Plan.

Verrica Pharmaceuticals files a revised proxy statement to correct errors and include additional data tagging, while also seeking stockholder approval for a reverse stock split.

Verrica Pharmaceuticals Inc. will hold its annual meeting on June 5, 2025, and is seeking stockholder votes on director elections, executive compensation, auditor ratification, and a potential reverse stock split.

Verrica Pharmaceuticals will hold its annual meeting on June 5, 2025, to vote on director elections, executive compensation, auditor ratification, and a potential reverse stock split.

Verrica Pharmaceuticals Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 6, 2024, outlining key proposals for shareholder voting.

Verrica Pharmaceuticals has announced its annual meeting of stockholders to be held on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.

Caligan Partners LP, a significant shareholder, has appointed Dr. Charles Frantzreb to the Board of Directors of Verrica Pharmaceuticals Inc., effective December 26, 2025.

Paul B. Manning and affiliated entities increased their beneficial ownership in Verrica Pharmaceuticals Inc. to 49.9% through recent purchases of common stock and warrants.

Caligan Partners LP and David Johnson have acquired a 9.99% beneficial ownership in Verrica Pharmaceuticals Inc. through a private placement, securing a board seat and expressing belief in the company's undervaluation.

Affinity Asset Advisors, LLC and Michael Cho have disclosed a 5.5% beneficial ownership stake in Verrica Pharmaceuticals Inc., including shares from warrants.

Affinity Asset Advisors, LLC and Affinity Healthcare Fund, LP have disclosed a combined beneficial ownership of 5.47% in Verrica Pharmaceuticals Inc.

Armistice Capital and Steven Boyd have reported a 6.77% beneficial ownership stake in Verrica Pharmaceuticals Inc., holding 639,193 shares.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Verrica Pharmaceuticals Inc.'s common stock as of March 31, 2025.

Perceptive Advisors LLC and its affiliated entities have filed an amended Schedule 13G, disclosing a 1.6% beneficial ownership stake in Verrica Pharmaceuticals, Inc., holding 1,481,481 shares through pre-funded warrants.

Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 9.99% in Verrica Pharmaceuticals Inc., totaling 9,235,571 shares of common stock.